FibroBiologics, Inc. announced the development of a novel artificial thymus organoid that can restore immune function in a severe combined immunodeficiency (SCID) mouse model. The organoid, composed of fibroblasts and thymus derived cells, is capable of generating mature and diverse T cells, including CD4, CD8, and regulatory T cells, in vitro and in vivo. FibroBiologics intends to develop this technology as a subcutaneous injection of an allogeneic fibroblast-based organoid to restore thymus function lost due to age-related natural thymus involution, and for a rapid restoration of the immune system in patients who have gone through chemotherapy.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5 USD | +5.49% |
|
-2.72% | 0.00% |
Jul. 01 | FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell Small Cap Completeness Index | CI |
Jul. 01 | FibroBiologics, Inc.(NasdaqGM:FBLG) added to Russell Microcap Growth Index | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 169M | |
+20.63% | 126B | |
+24.16% | 27.95B | |
-20.17% | 20.5B | |
-16.06% | 17.12B | |
-18.07% | 16.1B | |
-47.70% | 14.97B | |
+11.92% | 14.84B | |
+58.32% | 14.38B | |
+149.98% | 12.37B |
- Stock Market
- Equities
- FBLG Stock
- News FibroBiologics, Inc.
- Fibrobiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology